FDA approves second CAR-T therapy

A second chimeric antigen receptor (CAR) T-cell therapy has gained FDA approval, this time ...

High EZH2 expression a marker for death risk in RCC

FROM JOURNAL OF CLINICAL ONCOLOGY In patients with localized clear cell renal cell carcinoma ...

Biomarker predicts CYP17A1-inhibitor response in prostate cancer

FROM JAMA ONCOLOGY In patients with castration-resistant prostate cancer (CRPC), a variant of the ...

CDC: Forty percent of cancers linked to overweight or obesity

FROM MORBIDITY AND MORTALITY WEEKLY REPORT Being overweight or obese significantly increased the risk ...

ALL therapies grow, so do the complexities of choosing the order of treatments

EXPERT ANALYSIS FROM THE NCCN ANNUAL CONGRESS: HEMATOLOGIC MALIGNANCIES SAN FRANCISCO (FRONTLINE MEDICAL NEWS) ...

Dabrafenib/trametinib bests docetaxel for advanced NSCLC in indirect comparison

AT A SYMPOSIUM IN THORACIC ONCOLOGY CHICAGO (FRONTLINE MEDICAL NEWS) – Compared with docetaxel ...

It’s too soon to discard cotesting in cervical cancer

In their new cervical cancer screening draft recommendation statement, the U.S. Preventive Services Task ...

VCR regimen showed efficacy in mantle cell and indolent lymphomas

FROM LYMPHOMA, MYELOMA & LEUKEMIA The combination of bortezomib, cladribine, and rituximab (VCR) was ...

Rare type of MCL mimics Castleman disease

FROM PATHOLOGY – RESEARCH AND PRACTICE A rare type of mantle cell lymphoma (MCL) ...

[sam_pro id=0_12 codes="true"]
[sam_pro id=0_6 codes="false"]